Company profile: Silver Creek Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of protein therapeutics for cardiovascular disease and tissue repair, leveraging Smart Growth Factor technology to create growth factor fusion proteins for damaged tissues. Pipeline includes scp776, a targeted fusion protein in Phase II for acute ischemic stroke with preclinical efficacy in stroke, heart attack, and kidney injury, evaluated in the ARPEGGIO Phase II study for safety and neuroprotection.
Products and services
- Scp776: A targeted fusion protein under Phase II study for acute ischemic stroke, showing efficacy in preclinical models of stroke, heart attack, and kidney injury
- ARPEGGIO study: A Phase II clinical trial assessing scp776’s safety and neuroprotective capacity in acute ischemic stroke patients
- Smart Growth Factor™ technology: A fusion-protein–based technology that engineers growth factor fusion proteins aimed at treating damaged tissues and advancing protein therapeutics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Silver Creek Pharmaceuticals
Currie Medical
HQ: United States
Website
- Description: Provider of pneumatic compression devices and garments for DVT prevention, including the ALP DVT Prevention System and VasQcare home-based DVT/PE therapy; ReCur reprocessing services for collection of single-use devices; fluid warming drapes and systems; biohazard spill kits; and medical waste solidifiers to support safety, cost savings, and environmental impact reduction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Currie Medical company profile →
CH Biomedical
HQ: United States
Website
- Description: Provider of ventricular assist device (VAD) technology utilizing an innovative magnetic levitation pump design, including the CH-VAD®, an implantable left ventricular assist system using full magnetic levitation to support heart function in patients with end-stage heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CH Biomedical company profile →
Acesion Pharma
HQ: Denmark
Website
- Description: Provider of medical drugs for the treatment of atrial fibrillation, developing therapies that inhibit a heart cell ion channel. Offerings include AP30663, an intravenous drug for acute cardioversion to sinus rhythm with demonstrated efficacy in clinical trials, and AP31969, an oral drug for maintenance of sinus rhythm in patients with atrial fibrillation, currently in clinical development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acesion Pharma company profile →
AMI Cardiac Monitoring
HQ: United States
Website
- Description: Provider of ambulatory cardiac monitoring services for diagnostic outpatient arrhythmia monitoring, offering Holter monitors (multi-day, 24- or 48-hour, up to 7-day), mobile cardiac telemetry, and cardiac event monitoring. Services include patient and staff teaching guides, custom Holter summaries, rapid and STAT 24/7/365 report turnaround, and report delivery via WebPortal, fax, or secure email.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AMI Cardiac Monitoring company profile →
Artegraft
HQ: United States
Website
- Description: Provider of biologic vascular grafts derived from bovine carotid arteries, processed and sold for implantation primarily in hemodialysis patients, offering surgeons a biological alternative to synthetic grafts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Artegraft company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Silver Creek Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Silver Creek Pharmaceuticals
2.2 - Growth funds investing in similar companies to Silver Creek Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Silver Creek Pharmaceuticals
4.2 - Public trading comparable groups for Silver Creek Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →